Catalysts / LBRX
Upcoming FDA decisions and readouts we track for LB Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for LB Pharmaceuticals (LBRX, listed on Nasdaq). Both concern LB-102 (Schizophrenia; Bipolar depression).
First on the list: the Phase 3 readout for LB-102 (Schizophrenia), guided by the company to H1 2027. By stage, the upcoming rows are 1 Phase 2 readout and 1 Phase 3 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals LBRX · Nasdaq | LB-102 | Schizophrenia | H1 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| LB Pharmaceuticals LBRX · Nasdaq | LB-102 | Bipolar depression | Q1 2028 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList